Risk factors for COPD exacerbations in inhaled medication users: The COPDGene study biannual longitudinal follow-up prospective cohort

BMC Pulmonary Medicine

Volumn 16, Issue 1, 2016, Pages

  Busch, Robert ^a   Han, Meilan K ^b   Bowler, Russell P ^c   Dransfield, Mark T ^d,s   Wells, J Michael ^d,s   Regan, Elizabeth A ^c   Hersh, Craig P ^a,i   Crapo, James ^g   Silverman, Edwin ^g   Make, Barry ^g   Beaty, Terri ^g   Laird, Nan ^g   Lange, Christoph ^g   Cho, Michael ^g   Santorico, Stephanie ^g   Castaldi, Peter ^g   McDonald, Merry Lynn ^g   Wan, Emily ^g   Hardin, Megan ^g   Hetmanski, Jacqueline ^g   Parker, Margaret ^g   Hobbs, Brian ^g   El Boueiz, Adel ^g   Qiao, Dandi ^g   Halper Stromberg, Eitan ^g   Begum, Ferdouse ^g   Won, Sungho ^g   Coxson, Harvey O ^g   Hoffman, Eric A ^g   Humphries, Stephen ^g   Judy, Philip F ^g   Newell, John D ^u   Ross, James C ^g   Estepar, Raul San Jose ^g   Stoel, Berend C ^g   Tschirren, Juerg ^g   van Rikxoort, Eva ^g   van Ginneken, Bram ^g   Al Qaisi, Mustafa ^g   Gray, Teresa ^g   Kluiber, Alex ^g   Mann, Tanya ^g   Sieren, Jered ^g   Stinson, Douglas ^g   Schroeder, Joyce ^g   Van Beek, Edwin ^g   Jensen, Robert ^e   Everett, Douglas ^c   Faino, Anna ^c   Strand, Matt ^c   Wilson, Carla ^c   Hokanson, John E ^f   Kinney, Gregory ^f   Lutz, Sharon ^f   Young, Kendra ^f   Pratte, Katherine ^f   Lindsey Duca, M ^f   Curtis, Jeffrey L ^g   Martinez, Carlos H ^g   Pernicano, Perry G ^g   Hanania, Nicola ^h   Alapat, Philip ^h   Bandi, Venkata ^h   Atik, Mustafa ^h   Boriek, Aladin ^h   Guntupalli, Kalpatha ^h   Guy, Elizabeth ^h   Parulekar, Amit ^h   Nachiappan, Arun ^h   Demeo, Dawn ⁱ   Washko, George ⁱ   Jacobson, Francine ⁱ   Barr, R Graham ^j   Thomashow, Byron ^j   Austin, John ^j   D’souza, Belinda ^j   Pearson, Gregory D N ^j   Rozenshtein, Anna ^j   Macintyre, Neil ^k   Washington, Lacey ^k   McAdams, H Page ^k   McEvoy, Charlene ^l   Tashjian, Joseph ^l   Wise, Robert ^m   Hansel, Nadia ^m   Brown, Robert ^m   Horton, Karen ^m   Putcha, Nirupama ^m   Casaburi, Richard ⁿ   Adami, Alessandra ⁿ   Porszasz, Janos ⁿ   Fischer, Hans ⁿ   Budoff, Matthew ⁿ   Rossiter, Harry ⁿ   Sharafkhaneh, Amir ^o   Lan, Charlie ^o   Wendt, Christine ^g   Bell, Brian ^g   Foreman, Marilyn ^p   Westney, Gloria ^p   Berkowitz, Eugene ^p   Lynch, David A ^c   Rosiello, Richard ^q   Pace, David ^q   Criner, Gerard ^r   Ciccolella, David ^r   Cordova, Francis ^r   Dass, Chandra ^r   D’alonzo, Gilbert ^r   Desai, Parag ^r   Jacobs, Michael ^r   Kelsen, Steven ^r   Kim, Victor ^r   Mamary, A James ^r   Marchetti, Nathaniel ^r   Satti, Aditi ^r   Shenoy, Kartik ^r   Steiner, Robert M ^r   Swift, Alex ^r   Swift, Irene ^r   Vega Sanchez, Maria Elena ^r   Bailey, William ^s   Bhatt, Surya ^s   Nath, Hrudaya ^s   Ramsdell, Joe ^t   Friedman, Paul ^t   Soler, Xavier ^t   Yen, Andrew ^t   Cornellas, Alejandro ^u   Thompson, Brad ^u   Kazerooni, Ella ^b   Martinez, Carlos ^b   Billings, Joanne ^v   Allen, Tadashi ^v   Sciurba, Frank ^w   Chandra, Divay ^w   Weissfeld, Joel ^w   Fuhrman, Carl ^w   Bon, Jessica ^w   Anzueto, Antonio ^x   Adams, Sandra ^x   Maselli Caceres, Diego ^x   Ruiz, Mario E ^x   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c DEPARTMENT OF MEDICINE   (United States)

^d University of Alabama at Birmingham   (United States)

^e PFT QA Center   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g Baylor College of Medicine ^*

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j Duke University Medical Center ^*  (United States)

^k DUKE UNIVERSITY MEDICAL CENTER   (United States)

^l HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

^m JOHNS HOPKINS UNIVERSITY   (United States)

ⁿ HARBOR UCLA MEDICAL CENTER   (United States)

^o MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^p MOREHOUSE SCHOOL OF MEDICINE   (United States)

^q Reliant Medical Group Inc   (United States)

^r TEMPLE UNIVERSITY   (United States)

^s UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^t UNIVERSITY OF CALIFORNIA   (United States)

^u UNIVERSITY OF IOWA   (United States)

^v UNIVERSITY OF MINNESOTA   (United States)

^w UNIVERSITY OF PITTSBURGH   (United States)

^x UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

more..

Author keywords

Adrenergic beta agonists; Chronic obstructive pulmonary disease; COPD exacerbation; Inhaled corticosteroid; Inhaled medications; Long acting beta agonist; Prospective cohort study; Tiotropium

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE; LONG ACTING DRUG; SALBUTAMOL; SHORT ACTING DRUG; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GASTROESOPHAGEAL REFLUX; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; ST. GEORGE RESPIRATORY QUESTIONNAIRE; COMBINATION DRUG THERAPY; DISEASE COURSE; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; STATISTICAL MODEL;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; AGED; ASTHMA; BRONCHODILATOR AGENTS; COHORT STUDIES; COMORBIDITY; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GASTROESOPHAGEAL REFLUX; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SEX FACTORS; TIOTROPIUM BROMIDE;

EID: 84957553849     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/s12890-016-0191-7     Document Type: Article

References (40)

1. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128-38.
2. Anzueto A. Impact of exacerbations on COPD. Eur Respir Rev. 2010;19(116):113-8.
3. Anzueto A, Leimer I, Kesten S. Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J Chron Obstruct Pulmon Dis. 2009;4:245-51.
4. Spencer S, Calverley PM, Sherwood Burge P, Jones PW. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163(1):122-8.
5. Connors Jr AF, Dawson NV, Thomas C, Harrell Jr FE, Desbiens N, Fulkerson WJ, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med. 1996;154(4 Pt 1):959-67.
6. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418-22.
7. Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest. 2007;131(3):696-704.
8. Han MK, Kazerooni EA, Lynch DA, Liu LX, Murray S, Curtis JL, et al. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology. 2011;261(1):274-82.
9. Wells JM, Washko GR, Han MK, Abbas N, Nath H, Mamary AJ, et al. Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med. 2012;367(10):913-21.
10. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543-54.
11. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-89.
12. Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;5:CD007891.
13. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19-26.
14. Regan EA, Hokanson JE, Murphy JR, Make B, Lynch DA, Beaty TH, et al. Genetic epidemiology of COPD (COPDGene) study design. COPD. 2010;7(1):32-43.
15. Bowler RP, Kim V, Regan E, Williams A, Santorico SA, Make BJ, et al. Prediction of acute respiratory disease in current and former smokers with and without COPD. Chest. 2014;146(4):941-50.
16. Stewart JI, Moyle S, Criner GJ, Wilson C, Tanner R, Bowler RP, et al. Automated telecommunication to obtain longitudinal follow-up in a multicenter cross-sectional COPD study. COPD. 2012;9(5):466-72.
17. Hardin M, Silverman EK, Barr RG, Hansel NN, Schroeder JD, Make BJ, et al. The clinical features of the overlap between COPD and asthma. Respir Res. 2011;12:127.
18. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163(5):1256-76.
19. Team RDC. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2008.
20. Park SJ, Make B, Hersh CP, Bowler RP. Significance of Medication History at the Time of Entry into the COPDGene Study: Relationship with Exacerbation and CT Metrics. COPD. 2014;12(4):366-73.
21. Swift I, Satti A, Kim V, Make BJ, Newell J, Steiner RM, et al. Demographic, physiologic and radiographic characteristics of COPD patients taking chronic systemic corticosteroids. COPD. 2012;9(1):29-35.
22. Miravitlles M, Guerrero T, Mayordomo C, Sanchez-Agudo L, Nicolau F, Segu JL. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration. 2000;67(5):495-501.
23. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155-61.
24. Rascon-Aguilar IE, Pamer M, Wludyka P, Cury J, Coultas D, Lambiase LR, et al. Role of gastroesophageal reflux symptoms in exacerbations of COPD. Chest. 2006;130(4):1096-101.
25. Godtfredsen NS, Vestbo J, Osler M, Prescott E. Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. Thorax. 2002;57(11):967-72.
26. Garcia-Aymerich J, Farrero E, Felez MA, Izquierdo J, Marrades RM, Anto JM. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax. 2003;58(2):100-5.
27. Beeh KM, Glaab T, Stowasser S, Schmidt H, Fabbri LM, Rabe KF, et al. Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial. Respir Res. 2013;14:116.
28. van der Vaart H, Postma DS, Timens W, ten Hacken NH. Acute effects of cigarette smoke on inflammation and oxidative stress: a review. Thorax. 2004;59(8):713-21.
29. Tamimi A, Serdarevic D, Hanania NA. The effects of cigarette smoke on airway inflammation in asthma and COPD: therapeutic implications. Respir Med. 2012;106(3):319-28.
30. Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol. 2002;2(5):372-7.
31. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J. 2002;19(3):398-404.
32. Jones PW. St. George's Respiratory Questionnaire: MCID. COPD. 2005;2(1):75-9.
33. Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155(3):179-91.
34. Kesten S, Chapman KR. Physician perceptions and management of COPD. Chest. 1993;104(1):254-8.
35. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343-73.
36. Hardin M, Cho M, McDonald ML, Beaty T, Ramsdell J, Bhatt S, et al. The clinical and genetic features of COPD-asthma overlap syndrome. Eur Respir J. 2014;44(2):341-50.
37. Seemungal T, Stockley R, Calverley P, Hagan G, Wedzicha JA. Investigating new standards for prophylaxis in reduction of exacerbations--the INSPIRE study methodology. COPD. 2007;4(3):177-83.
38. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146(8):545-55.
39. Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285-94.
40. Gershon AS, Campitelli MA, Croxford R, Stanbrook MB, To T, Upshur R, et al. Combination long-acting beta-agonists and inhaled corticosteroids compared with long-acting beta-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA. 2014;312(11):1114-21.